Quoin Pharmaceuticals, Ltd.
For the period ended May 7, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 7, 2026 · Filed May 7, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Pipeline Programs:
Pipeline Programs:
Additional QRX003 Indications: Quoin continues to advance its Peeling Skin Syndrome (PSS) program, with the ongoing investigator-led study being expanded to six subjects. The Company plans to submit an IND to the FDA for PSS in Q2 of 2026.
QRX009 Development: Quoin also continues to advance its proprietary topical rapamycin platforms, which have achieved target loadings of 4% and 5% for the topical lotion and dermal patch, respectively. Investigator-led clinical studies are being planned for a number of indications including Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex and the Company is planning to submit an IND to the FDA for QRX009 for an additional indication before the end of Q3 of this year.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.